Novel themoresponsive intranasal technology presented at DDL 2022
Ab Initio Pharma, in partnership with Tetratherix & the Woolcock presented a new intranasal technology at Drug Delivery to the Lungs in Edinburgh in December, that offers formulators a toolbox for controlled administration of local and systemic molecules.
The innovative Tetratherix thermoresponsive gel technology (TP140). was presented as a promising drug carrier for sustained intranasal drug delivery. TP140 is in a liquid state at room temperature, enabling ease of administration from commercial nasal administration devices, however when deposited in the nasal cavity, undergoes a phase transition to form a mucoadhesive hydrogel that increases drug residence time, enhancing drug bioavailability.
Dr Juhura G. Almazi (Trisha) demonstrates innovative thermoresponsive intranasal gel technology at DDL2022
The paper was presented by Senior Scientist Dr Trisha G. Almazi.
The full paper can be found on the DDL website here.
